Dianthus Therapeutics, Inc. /DE/(DNTH)— Stock Profile, AI Score & Financials

Healthcare · Nasdaq · AI-powered stock analysis, 32-signal quality score, SEC EDGAR financials, and institutional holdings. Updated 2026-06-30.

Dianthus Therapeutics, Inc. /DE/ (DNTH) stock profile, AI quality score, and SEC EDGAR financial data, a Healthcare sector company. 13F Pro's AI-powered ranking engine scores DNTH at 22.6/100 on a 32-signal composite quality model, placing it at rank #2,746 of 2,961 stocks — the bottom half of the AI-ranked universe. DNTH scores in the top quartile across revenue growth (84.5). Areas of concern include free cash flow (1.2) and profitability (1.3), which score below median versus the broader universe. Shareholder dilution risk is elevated at 0.7/100, reflecting ongoing share issuance or stock-based compensation. Top institutional holders of DNTH by reported 13-F value include FMR, BlackRock, T. Rowe Price Investment Management, based on the most recent SEC filings. DNTH trades on the Nasdaq exchange and files with the SEC under CIK 1690585. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate DNTH daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for Dianthus Therapeutics, Inc. /DE/ directly from SEC EDGAR.